Cargando…
Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells
Non-small cell lung cancer (NSCLC) accounts for the majority (80–85%) of all lung cancers. All current available treatments have limited efficacy. The epidermal growth factor receptor (EGFR) plays a critical role in the development and progression of NSCLC, with high EGFR expression associated with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890653/ https://www.ncbi.nlm.nih.gov/pubmed/35235599 http://dx.doi.org/10.1371/journal.pone.0264717 |
_version_ | 1784661684683538432 |
---|---|
author | Kaewjanthong, Panthita Sooksai, Sarintip Sasano, Hironobu Hutvagner, Gyorgy Bajan, Sarah McGowan, Eileen Boonyaratanakornkit, Viroj |
author_facet | Kaewjanthong, Panthita Sooksai, Sarintip Sasano, Hironobu Hutvagner, Gyorgy Bajan, Sarah McGowan, Eileen Boonyaratanakornkit, Viroj |
author_sort | Kaewjanthong, Panthita |
collection | PubMed |
description | Non-small cell lung cancer (NSCLC) accounts for the majority (80–85%) of all lung cancers. All current available treatments have limited efficacy. The epidermal growth factor receptor (EGFR) plays a critical role in the development and progression of NSCLC, with high EGFR expression associated with increased cell proliferation and poor prognosis. Thus, interfering with EGFR signaling has been shown to effectively reduce cell proliferation and help in the treatment of NSCLC. We previously demonstrated that the progesterone receptor (PR) contains a polyproline domain (PPD) that directly interacts with Src homology 3 (SH3) domain-containing molecules and expression of PR-PPD peptides inhibits NSCLC cell proliferation. In this study, we investigated whether the introduction of PR-PPD by cell-penetrating peptides (CPPs) could inhibit EGF-induced cell proliferation in NSCLC cells. PR-PPD was attached to a cancer-specific CPP, Buforin2 (BR2), to help deliver the PR-PPD into NSCLC cells. Interestingly, addition of BR2-2xPPD peptides containing two PR-PPD repeats was more effective in inhibiting NSCLC proliferation and significantly reduced EGF-induced phosphorylation of Erk1/2. BR2-2xPPD treatment induced cell cycle arrest by inhibiting the expression of cyclin D1 and CDK2 genes in EGFR-wild type A549 cells. Furthermore, the combination treatment of EGFR-tyrosine kinase inhibitors (TKIs), including Gefitinib or Erlotinib, with BR2-2xPPD peptides further suppressed the growth of NSCLC PC9 cells harboring EGFR mutations as compared to EGFR-TKIs treatment alone. Importantly, BR2-2xPPD peptides mediated growth inhibition in acquired Gefitinib- and Erlotinib- resistant lung adenocarcinoma cells. Our data suggests that PR-PPD is the minimal protein domain sufficient to inhibit NSCLC cell growth and has the potential to be developed as a novel NSCLC therapeutic agent. |
format | Online Article Text |
id | pubmed-8890653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-88906532022-03-03 Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells Kaewjanthong, Panthita Sooksai, Sarintip Sasano, Hironobu Hutvagner, Gyorgy Bajan, Sarah McGowan, Eileen Boonyaratanakornkit, Viroj PLoS One Research Article Non-small cell lung cancer (NSCLC) accounts for the majority (80–85%) of all lung cancers. All current available treatments have limited efficacy. The epidermal growth factor receptor (EGFR) plays a critical role in the development and progression of NSCLC, with high EGFR expression associated with increased cell proliferation and poor prognosis. Thus, interfering with EGFR signaling has been shown to effectively reduce cell proliferation and help in the treatment of NSCLC. We previously demonstrated that the progesterone receptor (PR) contains a polyproline domain (PPD) that directly interacts with Src homology 3 (SH3) domain-containing molecules and expression of PR-PPD peptides inhibits NSCLC cell proliferation. In this study, we investigated whether the introduction of PR-PPD by cell-penetrating peptides (CPPs) could inhibit EGF-induced cell proliferation in NSCLC cells. PR-PPD was attached to a cancer-specific CPP, Buforin2 (BR2), to help deliver the PR-PPD into NSCLC cells. Interestingly, addition of BR2-2xPPD peptides containing two PR-PPD repeats was more effective in inhibiting NSCLC proliferation and significantly reduced EGF-induced phosphorylation of Erk1/2. BR2-2xPPD treatment induced cell cycle arrest by inhibiting the expression of cyclin D1 and CDK2 genes in EGFR-wild type A549 cells. Furthermore, the combination treatment of EGFR-tyrosine kinase inhibitors (TKIs), including Gefitinib or Erlotinib, with BR2-2xPPD peptides further suppressed the growth of NSCLC PC9 cells harboring EGFR mutations as compared to EGFR-TKIs treatment alone. Importantly, BR2-2xPPD peptides mediated growth inhibition in acquired Gefitinib- and Erlotinib- resistant lung adenocarcinoma cells. Our data suggests that PR-PPD is the minimal protein domain sufficient to inhibit NSCLC cell growth and has the potential to be developed as a novel NSCLC therapeutic agent. Public Library of Science 2022-03-02 /pmc/articles/PMC8890653/ /pubmed/35235599 http://dx.doi.org/10.1371/journal.pone.0264717 Text en © 2022 Kaewjanthong et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kaewjanthong, Panthita Sooksai, Sarintip Sasano, Hironobu Hutvagner, Gyorgy Bajan, Sarah McGowan, Eileen Boonyaratanakornkit, Viroj Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title_full | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title_fullStr | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title_full_unstemmed | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title_short | Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells |
title_sort | cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits egf signaling and cell proliferation in lung cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890653/ https://www.ncbi.nlm.nih.gov/pubmed/35235599 http://dx.doi.org/10.1371/journal.pone.0264717 |
work_keys_str_mv | AT kaewjanthongpanthita cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT sooksaisarintip cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT sasanohironobu cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT hutvagnergyorgy cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT bajansarah cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT mcgowaneileen cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells AT boonyaratanakornkitviroj cellpenetratingpeptidescontainingtheprogesteronereceptorpolyprolinedomaininhibitsegfsignalingandcellproliferationinlungcancercells |